Allen D G, Baak J, Belpomme D, Berek J S, Bertelsen K, ten Bokkel Huinink W W, van der Burg M E, Calvert A H, Conte P F, Dauplat J
Department of Internal Medicine, Utrecht University Hospital, The Netherlands.
Ann Oncol. 1993;4 Suppl 4:83-8. doi: 10.1093/annonc/4.suppl_4.s83.
Over the last few days of a 5-day international workshop held in June 1993, a group of specialists in the field of advanced epithelial ovarian cancer tried to reach consensus on a number of issues with implications for standard practice and for research.
Five groups of experts considered several issues which included: biologic factors, prognostic factors, surgery, management recommendations, dose intensity, supportive care, drug resistance, second-line treatment, investigational drugs, and tumour markers. Discussing the management recommendations, the group attempted to arrive at answers to four questions: Is there in fact a cure rate for advanced ovarian carcinoma? Are there prognostic factors which help to identify patients who will not do well with current therapy? What is the current best therapy for advanced ovarian carcinoma? What directions should research take in advanced ovarian cancer? In a plenary meeting these issues were discussed.
Consensus statements were achieved on all topics mentioned above. This article reports on the statements written by the chairmen and approved by the consensus group.
在1993年6月举办的为期5天的国际研讨会的最后几天里,一组晚期上皮性卵巢癌领域的专家试图就一些对标准治疗和研究有影响的问题达成共识。
五组专家审议了若干问题,包括:生物学因素、预后因素、手术、治疗建议、剂量强度、支持治疗、耐药性、二线治疗、试验性药物和肿瘤标志物。在讨论治疗建议时,该小组试图回答四个问题:晚期卵巢癌实际上有治愈率吗?是否存在有助于识别对当前治疗反应不佳的患者的预后因素?晚期卵巢癌目前的最佳治疗方法是什么?晚期卵巢癌的研究应朝什么方向发展?在全体会议上讨论了这些问题。
就上述所有主题达成了共识声明。本文报告了由主席撰写并经共识小组批准的声明。